Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Bristol-myers squibb company save search
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Published: 2023-09-26 (Crawled : 14:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.49%
H: 0.65%
C: -0.56%
therapeutics milestone
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
Published: 2022-05-10 (Crawled : 16:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: 7.05%
H: 11.01%
C: 8.75%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.72%
H: 0.23%
C: -0.69%
partnership
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
Published: 2022-04-12 (Crawled : 12:20) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: -3.6%
H: 0.79%
C: -3.74%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.37%
H: 1.05%
C: 0.43%
collaboration designation
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.17%
H: 0.11%
C: -0.39%
program
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2021-11-23 (Crawled : 12:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
europe approval ulcerative colitis
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
Published: 2021-10-21 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.03%
H: 0.02%
C: -0.48%
europe therapy approval her2+ her2- her2 nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Published: 2021-10-01 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
treatment europe cardio mavacamten application
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
Published: 2021-10-01 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
treatment europe antibody nivolumab
BioSpace Movers & Shakers, Sept. 24
Published: 2021-09-24 (Crawled : 15:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.31%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
space spac
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -2.6%
H: 6.97%
C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Published: 2021-08-19 (Crawled : 16:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.41%
H: 2.16%
C: 1.27%
europe therapy approval car-t t-cell
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published: 2021-07-30 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
disease treatment europe therapy cancer iot approval nivolumab
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
Published: 2021-06-18 (Crawled : 18:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.55%
H: 0.5%
C: 0.11%
myeloid leukemia europe therapy leukemia approval acute myeloid leukemia
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published: 2021-04-14 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 1.09%
C: 0.35%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.38%
H: 4.2%
C: 3.09%
treatment europe renal approval cell carcinoma nivolumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.